Physician profile
Ashley Woodruff
NPI 1518340496
$3,526.23
in general payments reported to CMS, 2019-2025
22 companies · $2,079 in 2025
The $2,079 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $425 · 2023: $315 · 2024: $443 · 2025: $2,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022 · Travel and Lodging: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.73 |
| Travel and Lodging | $814.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,784.10 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $589.03 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $256.94 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.58 | 2021-2023 | Jardiance |
| Philips North America LLC | $110.37 | 2022-2025 | Ecc Solutions |
| Amgen INC. | $98.48 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $83.17 | 2022-2025 | Wavewriter Alpha Prime 16, Comet |
| Medtronic, INC. | $67.16 | 2025 | Ffrangio |
| Bayer Healthcare Pharmaceuticals INC. | $61.65 | 2021-2025 | |
| Abiomed | $47.52 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $41.36 | 2021-2022 | |
| Averitas Pharma INC. | $38.41 | 2024 | Qutenza |
| Cardiva Medical, INC. | $29.77 | 2024-2025 | Optowire |
| Janssen Pharmaceuticals, INC | $23.67 | 2024 | Xarelto |
| Siemens Medical Solutions USA, INC. | $23.21 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.09 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.83 | 2025 | Amvuttra |
| Novo Nordisk INC | $19.38 | 2023 | Ozempic, Rybelsus |
| Abbott Laboratories | $19.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.12 | 2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $17.18 | 2021 | |
| Merck Sharp & Dohme LLC | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Woodruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.